Cathepsin L (CTSL)
The application of nanotechnology in medicine has been a hot topic in recent years. But a new study by British scientists shows that when bionic nanoparticles enter human cells, the layer of proteins attached to the surface of the nanoparticles is degraded by the CTSL.
The results were published in the September 22 issue of ACS nano. The use of nanoparticles to deliver therapeutic protein molecules to cells is one of the promising applications of nanotechnology in medicine.Nanoparticles often cover a layer of molecules, usually proteins, to determine how the nanoparticles behave once they enter the cell.
Researchers at the university of Liverpool in the United Kingdom confirmed that in many cells, nanoparticles enter the endosome, and that the endosome's CTST degrades the crucial protein layers that the nanoparticles coat. One of the paper's authors, Dr Vioglyna sell of the university of Liverpool, said the use of nanoparticles as a drug delivery tool was promising, but that the outer proteins of the particles would have to remain highly intact for such a biological treatment to work, but the degradation of the CTST would make it less effective.
This finding undoubtedly poses a new challenge to current research on the medical application of nanotechnology, and means that any future design of intracellular nano-elements will take into account the degradation of the CTST, either by enabling it to bypass the endosome or by having a component that inhibits the protease. The lead researcher on the project, Dr Rafael levy of the university of Liverpool, said they could now measure the position and state of the nanoparticles quickly and in large quantities, which would help the goal.
At present, DLDEVELOP co. LTD has developed corresponding CTSL Elisa products. To get more information, you could contact our professional staff directly or directly to our website:
http://www.dldevelop.com/Research-reagent/dl-ctsl-hu.html http://www.dldevelop.com/Research-reagent/dl-ctsl-mu.html http://www.dldevelop.com/Research-reagent/dl-ctsl-p.html http://www.dldevelop.com/Research-reagent/dl-ctsl-ra.html
The results were published in the September 22 issue of ACS nano. The use of nanoparticles to deliver therapeutic protein molecules to cells is one of the promising applications of nanotechnology in medicine.Nanoparticles often cover a layer of molecules, usually proteins, to determine how the nanoparticles behave once they enter the cell.
Researchers at the university of Liverpool in the United Kingdom confirmed that in many cells, nanoparticles enter the endosome, and that the endosome's CTST degrades the crucial protein layers that the nanoparticles coat. One of the paper's authors, Dr Vioglyna sell of the university of Liverpool, said the use of nanoparticles as a drug delivery tool was promising, but that the outer proteins of the particles would have to remain highly intact for such a biological treatment to work, but the degradation of the CTST would make it less effective.
This finding undoubtedly poses a new challenge to current research on the medical application of nanotechnology, and means that any future design of intracellular nano-elements will take into account the degradation of the CTST, either by enabling it to bypass the endosome or by having a component that inhibits the protease. The lead researcher on the project, Dr Rafael levy of the university of Liverpool, said they could now measure the position and state of the nanoparticles quickly and in large quantities, which would help the goal.
At present, DLDEVELOP co. LTD has developed corresponding CTSL Elisa products. To get more information, you could contact our professional staff directly or directly to our website:
http://www.dldevelop.com/Research-reagent/dl-ctsl-hu.html http://www.dldevelop.com/Research-reagent/dl-ctsl-mu.html http://www.dldevelop.com/Research-reagent/dl-ctsl-p.html http://www.dldevelop.com/Research-reagent/dl-ctsl-ra.html
